WALTHAM, Mass., Aug. 31, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced today that management will present at the following upcoming fall financial conferences:
- Robert W. Baird Healthcare Conference, New York, NY, September 8 at 8:30 AM ET
- Sach’s 11th Annual Biotech in Europe Investor Forum, Zurich, Switzerland, September 13, 11:15 AM CEST oncology panel and 12:15 PM CEST corporate presentation
- UBS Global Life Sciences Conference, New York, NY, September 19 at 4:00 PM ET
- Sofinnova BioPartnering Conference 2011, Tokyo, Japan, October 4, time to be determined. Please visit http://www.sofinnovajapanpartnering.com/program.php for the schedule.
- 10th Annual BIO Investor Forum, San Francisco, CA, October 25 to 26, exact date and time to be determined. Please visit http://www3.bio.org/investorforum/presenting-companies/2011/ for the schedule.
Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company’s intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator. Syndax has worldwide rights to develop and commercialize entinostat and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures. For more information please visit www.syndax.com.
Contact Information
E. Blair Schoeb
Syndax Pharmaceuticals, Inc
Tel: 908-277-0386
bschoeb@syndax.com
SOURCE Syndax Pharmaceuticals, Inc.
